

### **Amendments to the Claims:**

This listing of the claims will replace all prior versions, and listings, of claims in the present application.

### **Listing of Claims:**

1-33 (canceled).

34 (currently amended). A method of treating a disease or disorder in a human comprising administering to a human in need of such treatment a therapeutically effective amount of a molecule which antagonizes the function of a human Notch protein, in which the disease or disorder is a malignancy characterized by increased Notch activity or increased expression of a human Notch protein or of a Notch derivative capable of being bound by an antibody to a human Notch protein, relative to said Notch activity or expression in an analogous non-malignant sample, wherein said molecule is (i) a protein capable of inhibiting the interaction of said human Notch protein with another toporythmic protein, or (ii) an antibody to said human Notch protein or a portion of said antibody containing the idiotype thereof, or (iii) an oligonucleotide which (a) consists of at least six nucleotides, (b) consists of at least a sequence complementary to at least a portion of a RNA transcript of a toporythmic gene; and (c) is hybridizable to the RNA transcript.

Claim 35-90 (canceled).

91 (previously presented). The method according to claim 34, in which the disease or disorder is cervical cancer.

92 (previously presented). The method according to claim 34, in which the disease or disorder is breast cancer.

93 (previously presented). The method according to claim 34, in which the disease or disorder is colon cancer.

94 (previously presented). The method according to claim 34, in which the malignancy is selected from the group consisting of melanoma, seminoma, and lung cancer.

95 (canceled).

96 (previously presented). The method according to claim 34, 91, 92 or 93, in which the molecule is an antibody to said human Notch protein or a portion of said antibody containing the idiotype thereof.

97 (previously presented). The method according to claim 96, in which the antibody is a neutralizing antibody.

98 (previously presented). The method according to claim 96, in which the antibody is monoclonal.

99 (previously presented). The method according to claim 97, in which the neutralizing antibody is monoclonal.

100 (previously presented). The method according to claim 97, in which the neutralizing antibody or portion of said antibody containing the idiotype thereof binds to a human Notch protein but does not bind to a *Drosophila* Notch protein.

101 (withdrawn). The method according to claim 34, 91, 92 or 93, in which the molecule is a protein consisting of at least the extracellular domain of a Notch protein or a portion thereof capable of binding to a Notch ligand.

102 (withdrawn). The method according to claim 34, 91, 92 or 93, in which the molecule is a protein consisting of at least the EGF homologous repeats of a Notch protein.

103 (withdrawn). The method according to claim 34, 91, 92 or 93, in which the molecule is a protein consisting of at least the EGF-like repeats 11 and 12 of a Notch protein.

104 (withdrawn). The method according to claim 34, 91, 92 or 93, in which the molecule is a protein consisting of at least an adhesive fragment of a Notch protein, the fragment being characterized by the ability to bind to a Delta protein or Serrate protein.

105 (withdrawn, currently amended). The method according to claim 34, 91, 92 or 93, in which the molecule is said an oligonucleotide, wherein said oligonucleotide ~~which (a) consists of at least six nucleotides; (b) consists of at least a sequence complementary to at least a portion of a RNA transcript of a Notch gene; and (c) is hybridizable to the RNA transcript.~~

106 (withdrawn). The method according to claim 34, in which the molecule is an antibody to a Delta protein or Serrate protein, or a portion of the antibody containing the idiotype thereof.

Claim 107 (canceled).

108 (withdrawn). The method according to claim 106, in which the antibody binds to a fragment of a Delta protein or Serrate protein, the fragment being characterized by the ability to bind to a Notch protein.

109 (withdrawn). The method according to claim 106, in which the antibody is monoclonal.

110 (withdrawn). The method according to claim 106, in which the antibody is a neutralizing antibody.

111 (withdrawn). The method according to claim 34, in which the molecule is a protein consisting of at least a fragment of a Delta protein or Serrate protein, the fragment being characterized by the ability to bind to a Notch protein.

Claim 112 (canceled).

113 (withdrawn). The method according to claim 34, in which the molecule is a Notch protein.

114 (withdrawn). The method according to claim 34, in which the molecule is encoded by a gene which is a member of the Notch signaling pathway.

115 (previously presented). The method according to claim 34, in which the molecule interferes with Notch intracellular signal transduction.

116 (withdrawn). The method according to claim 34, in which the molecule is an analog or competitive inhibitor of a Notch intracellular signal transducing region.